Chief Executive Officer & Portfolio Manager
Joseph founded Perceptive Advisors, LLC in 1999. Previously, he was Senior Analyst at Aries Fund, a Paramount Capital Asset Management biotechnology hedge fund, from November 1994 through December 1998. Prior, he was Senior Biotechnology Analyst at Prudential Securities for four years. He started his career in the healthcare sector of the securities industry as Biotechnology Analyst at Labe, Simpson. Joseph earned an M.B.A. from New York University and a B.A., magna cum laude, in psychology from the University of California San Diego.
Chief Investment Officer
In 2006 Adam Stone joined Perceptive. Prior to Perceptive he was a senior analyst at Ursus Capital. During his five years there he focused on biotech and specialty pharmaceuticals. He graduated, with honors, from Princeton University with a B.A. in molecular biology. Adam serves on the board of directors for several of Perceptive’s portfolio companies, including Solid Biosciences, Renovia, and Xontogeny. Additionally, Adam serves as the CEO of ARYA Sciences Acquisition Corp, and he is a member of Perceptive’s internal investment committees for the credit opportunities and venture funds.
Portfolio Manager, Credit
Sam Chawla brings over 15 years of experience in healthcare corporate finance to Perceptive. Prior to joining in 2013, he was Managing Director in the Global Healthcare Group at UBS Investment Bank. Sam has in-depth experience in M&A advisory, underwriting debt and equity financings across healthcare. He graduated from Johns Hopkins University with a B.A. in Economics and from Georgetown University with a MBA.
Michael Altman, CFA
Michael Altman joined Perceptive in 2007 and is a managing director on the investment team. His focus is on medical devices, diagnostics, digital health and Specialty Pharmaceuticals. He is also a member of the investment committee for the credit opportunities fund. Additionally, Michael serves as the CFO of ARYA Sciences Acquisition Corp. Prior to Perceptive he was a healthcare trader and analyst at First New York Securities. Michael graduated from the University of Vermont with a B.S. in Business Administration. Michael serves on the board of directors for Lyra Therapeutics and Vitruvius Therapeutics.
Hossein Ekrami, PH.D.
Hossein Ekrami joined Perceptive in 2007 from healthcare hedge fund Ursus Capital, where he was a Senior Analyst focused on specialty pharmaceuticals, generics, and biotech for more than seven years. Hossein earned his Ph.D. at the University of Southern California and his undergraduate degree, with honors, from London University.
Ellen Hukkelhoven, PH.D.
Ellen Hukkelhoven joined Perceptive in 2013 as a Senior Biotechnology Analyst. At Perceptive, she focuses on public and private development stage therapeutic companies. Ellen serves on the boards of MeiraGTx and Partner Therapeutics. Prior to Perceptive, Ellen received her PhD in Cancer Biology from Memorial Sloan Kettering Cancer Center. During her tenure at MSKCC, she founded and built the life sciences division of InSITE, a top graduate fellowship program that helps early stage companies with their most pressing needs. Ellen graduated magna cum laude from Princeton University with degrees in molecular biology and finance.
Craig Yeshion, MD
Craig Yeshion joined Perceptive in 2016. Prior to joining the firm he was a Portfolio Manager for J. Goldman & Co. covering medical devices and diagnostics from 2012 through 2016. Prior to J. Goldman, he spent 5 years covering medical devices, and biotechnology as a Senior Analyst for Accipiter Capital Management, and 6 years as an analyst for Ursus Capital. Craig received his Medical degree with Honors from the Cornell University Medical College in 1995. He completed his Internal Medicine residency at New York Hospital Cornell Medical Center, and was a physician in private practice from 1995-2000. He received a B.A. in Economics from the University of Pennsylvania.
Weston Nichols, PH.D.
Weston Nichols joined Perceptive in 2016 from Balyasny Asset Management where he was a biotech analyst. He earned his Ph.D. in neuroscience from Caltech, and undergraduate degree in biological engineering from Cornell.
Keyvan Mirsaeedi-Farahani, MD
Keyvan Mirsaeedi-Farahani joined Perceptive in 2016 after earning an MD from the University of Pennsylvania and an MBA from the Harvard Business School. He previously spent two years as an analyst with McKinsey. Keyvan graduated Phi Beta Kappa from the University of Michigan with a BS in molecular biology as well as an undergraduate business degree.
Greg Raffo joined Perceptive in February, 2010 from Grace Financial Group, a brokerage firm, where he was a sales trader covering the healthcare space. Prior to that he was an equity research analyst for Boenning & Scattergood, Inc. where he covered financial companies. Greg graduated from Wake Forest University in 2003 with a BS in Business.
Chief Credit Officer
Sandeep Dixit brings 15 years of experience to Perceptive. He was formerly Managing Director, Fort Hill Investment Partners and a Vice President at Fortress Investment Group, Drawbridge Special Opportunities Fund. Sandeep has an extensive credit structuring, underwriting and portfolio management background encompassing direct lending, leveraged loans and high yield bonds. He graduated cum laude with a B.S. in Economics from The Wharton School, University of Pennsylvania.
Portfolio Manager – Venture
Chris Garabedian founded Xontogeny in June of 2016 to support multiple promising technologies from early development through clinical proof of concept, and formed a partnership with Perceptive in 2017 to establish the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Chris will help source and identify venture opportunities for investment as part of the Xontogeny portfolio and beyond. Chris has a broad base of experience and a track record of success across his 25 years in the pharma and biotech industries, including at two of the most successful biopharma companies over the last 20 years, Gilead and Celgene. Most recently, Chris served as the President and CEO of Sarepta Therapeutics from 2011 to 2015, overseeing the turnaround of a company that is now a commercial stage leader in the genetic technology space after leading the development of the company’s Duchenne Muscular Dystrophy program. Prior to Sarepta, Chris served as VP of Corporate Strategy for Celgene from 2007 to 2010. Prior to Celgene, Chris served in a number of global leadership roles at Gilead from 1997 to 2005, including as VP of Corporate Development, VP of Medical Affairs and VP of Marketing. Chris is currently on the Board of Directors of MassBio, on the Board of Advisors for the Keck Graduate Institute and serves as a Senior Advisor for the Boston Consulting Group.
Corporate Development – Venture
Fred Callori joined Xontogeny in September 2017 to support the company’s strategic and operational objectives, including providing overall corporate governance, transactional, and strategic advice to Xontogeny’s portfolio of companies. Fred also joined Perceptive in September 2017 to support the firm’s venture fund strategy. As a member of the Perceptive Investment Team, Fred will help source and evaluate venture opportunities for investment as part of the Xontogeny portfolio and beyond. Fred developed deep experience working with early stage life science companies as a partner in the Life Science and Emerging Companies practices of Choate, Hall & Stewart LLP, a Boston law firm ranked among the most active firms worldwide for private equity and venture capital deals. During his 20 year tenure at Choate, Fred advised clients on the formation, structure, financing and overall corporate development of early stage and emerging life science companies, including representing leading venture capital and institutional investment firms focused on investing in the sector. Fred holds a JD from Boston University School of Law and a BA in Economics from Binghamton University.
Randy joined Perceptive in 2018 as an Analyst. Prior to Perceptive, he spent two years as a Senior Analyst in the Healthcare group at CIT. Randy graduated summa cum laude from Rutgers University with a B.S. in both Biomedical Engineering and Economics.
Harry Jenq, PhD.
Harry Jenq joined Perceptive in 2018 from Millennium Management where he was an analyst focused on the biotech sector. He earned his Ph.D. in bioengineering from Harvard/MIT, and graduated magna cum laude from Princeton University with degrees in molecular biology and computer science (minor).
Kunal joined Perceptive in 2018 and focuses on public and private biotech companies. Previously, he spent five years in business development at Agios Pharmaceuticals and as a biopharma strategy consultant at Putnam Associates. He also spent time in corporate and commercial strategy at Novartis and Sanofi-Genzyme. Kunal holds an M.B.A. in Healthcare Management and Finance from the Wharton School and a B.A. in Economics with honors from the University of Pennsylvania.
Chief Operating Officer
Jim Mannix has been at Perceptive since 2006, where he manages the business operations. He has 23 years of experience as a COO, trader and portfolio manager in the equity, options, futures and debt markets. Before joining Perceptive, Jim was COO and Head Trader of the Medici Healthcare Fund, a healthcare sector specific hedge fund that he helped launch. Prior to Medici, he worked as a Portfolio Manager for ETG, LLC, where he managed long and short U.S. equities and options. Prior, he worked at Lehman Brothers as both an equity and debt trader. He graduated with a B.A. from Boston College.
Chief Financial Officer
Peter Fierro joined Perceptive in 2007 and is responsible for all aspects of the funds’ accounting. Prior to joining Perceptive, he was a manager at Rothstein, Kass & Co., P.C. (now KPMG LLP) and BISYS-RK Alternative Investment Services, Inc. (now SS&C Globe Op) where he gained 7 years’ experience auditing and administering various hedge fund portfolios. Peter graduated with highest honors from Rutgers University where he earned a bachelor’s degree in accounting. He is a certified public accountant, and a member of the American Institute of Certified Public Accountants (AICPA) and the New Jersey Society of Certified Public Accountants (NJSCPA).
Chief Compliance Officer
Alexander Rakitin is the Chief Compliance Officer. Prior to joining Perceptive in 2017, Mr. Rakitin was a Senior Compliance Officer responsible for all aspects of the compliance program for the Ventures and Private Investments divisions at Two Sigma Investments where he worked since 2012. Prior to taking on those responsibilities at Two Sigma, Alex was responsible for the firm’s Core Compliance program as well as the compliance program for marketing and investor communications across the Asia-Pacific region. Before joining Two Sigma, Alex worked at Owl Creek Asset Management and GlobeOp Investor Services while pursuing a Law Degree at New York Law School. He graduated from Brooklyn College with a B.S. degree and is a member of the New York State Bar Association.
Director of Investor Relations & Marketing
Patrick Morrow is the Director of Investor Relations & Marketing. Prior to joining Perceptive in 2017, Patrick was Vice President in the Private Capital Group at Jefferies LLC which raised over $13 billion of institutional capital for private equity funds and private financings during his tenure. Previously, he was an Investment Banking Analyst in the Recapitalization & Restructuring Group at Jefferies LLC. Mr. Morrow graduated from The Ohio State University with a B.A. in International Studies focusing on World Economy & Business.
Samuel Cohn is responsible for managing the financial operations for the credit and venture funds, and assists in this area across the firm. Sam joined Perceptive in 2016 from Fortress Investment Group where he was a Senior Accountant working on the Fortress Credit Opportunities Funds. Prior to that, he was an associate at Deloitte LLP focused on the audits of private equity funds. Sam received a BA from Fairleigh Dickinson University, an MBA from Rutgers Business School and is a licensed Certified Public Accountant in the State of New York.
Steven Berger joined Perceptive in 2006 as Operations Manager. Prior to this, Steve worked at First New York Securities, LLC as both a Senior Operations Representative and an operations Manager from 1992 to 2006. Prior Mr. Berger was an Operations Manager with Dean Witter Reynolds for six years. Steven received an Associate’s Degree in Business Administration from Kingsborough Community College.
Investor Relations & Administration
Louisa Rivera has been at Perceptive since 2004, assisting the Portfolio Manager and COO in the day-to-day business operations. Prior to this she was Administrative Manager for Josephson, Luxenberg & Kance, P.C., CPA. Louisa also worked at Lehman Brothers as an Executive Assistant in the Investment Banking Division. Ms. Rivera attended LaGuardia College where she majored in Business Administration.
Allison Benmen joined the Perceptive team in 2015, providing administrative support to the Chief Investment Officer and Senior Analysts in day-to-day business operations. Prior to this, she was an Event Coordinator for NYC based hospitality company The Line Group. Allison attended Indiana University where she majored in Tourism, Hospitality, and Event Management.
Brooke Becker started at Perceptive in February 2016. She is responsible for all receptionist duties and keeping our office up and running on a daily basis. Brooke attended The University of Texas at San Antonio, where she majored in Communications.
Nicole Glebocki, CPA
Nicole Glebocki joined Perceptive in 2018 as Fund Accountant. Prior to this, Nicole worked at HedgeServ where she was a Fund Accounting Manager with experience on the Client Onboarding/Implementation team. She also worked in forensic accounting and business valuation as a Financial Analyst at Financial Research Associates and as a Senior Audit Associate in financial services practice at KPMG. Nicole earned a bachelor’s degree in Accounting and Finance from Salisbury University and is a licensed Certified Public Accountant in the State of New York.